Clinical Trials Logo
  1. Home
  2. Beta-Thalassemia
  3. NCT00790127

Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

Beta Thalassemia Clinical Trial

Official title:
A Multi-National, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HQK-1001 in Subjects With Beta Thalassemia Intermedia, Including Hemoglobin E Beta Thalassemia

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of HQK-1001 administered daily for 8 weeks in subjects with beta thalassemia intermedia

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00790127
Study type Interventional
Source HemaQuest Pharmaceuticals Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date March 2009
Completion date May 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT01049854 - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase 2
Active, not recruiting NCT00408447 - Stem Cell Transplant in Sickle Cell Disease and Thalassemia Phase 2
Completed NCT02597595 - Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major N/A
Recruiting NCT06073860 - A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
Recruiting NCT05357482 - Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia Phase 1/Phase 2
Completed NCT00005934 - 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia Phase 2
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Completed NCT00159042 - Genetic Factors Affecting the Severity of Beta Thalassemia N/A
Recruiting NCT04929574 - Evaluation of Heart Status in Patients of Beta Thalassemia Using Echocardiogram
Recruiting NCT04918056 - Genetic Variants Affecting the Clinical Severity of Beta Thalassemia
Completed NCT00001958 - Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia) Phase 2
Recruiting NCT04917978 - Association of Hb F Level With Clinical Severity of Beta Thalassemia